Systematically higher Ki67 scores on core biopsy samples compared to corresponding resection specimen in breast cancer: A multi-operator and multi-institutional study

The International Ki67 in Breast Cancer Working Group of the Breast International Group & North American Breast Cancer Group  (BIG-NABCG)

Systematically higher Ki67 scores on core biopsy samples compared to corresponding resection specimen in breast cancer: A multi-operator and multi-institutional study

The International Ki67 in Breast Cancer Working Group of the Breast International Group & North American Breast Cancer Group (BIG-NABCG)

Deanery of Molecular, Genetic and Population Health Sciences

Research output: Contribution to journal › Article › peer-review

Original language	English
Journal	Modern Pathology
Publication status	Published - 21 Jun 2022

Access to Document

s41379-022-01104-9
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder
Final published version, 3.44 MB

Cite this

@article{8c985a58d6544de88131738ec92e8b5b,

title = "Systematically higher Ki67 scores on core biopsy samples compared to corresponding resection specimen in breast cancer: A multi-operator and multi-institutional study",

author = "{The International Ki67 in Breast Cancer Working Group of the Breast International Group & North American Breast Cancer Group (BIG-NABCG)} and Balazs Acs and {C.Y. Leung}, Samuel and {M. Kidwell}, Kelley and Indu Arun and Renaldas Augulis and {S Badve}, Sunil and Yalai Bai and {L Bane}, Anita and John Bartlett and Jane Bayani and Gilbert Bigras and Annika Blank and Henk Buikema and {C. Chang}, Martin and {L. Dietz}, Robin and Andrew Dodson and Susan Fineberg and {M. Focke}, Cornelia and Dongxia Gao and {M. Gown}, Allen and Carolina Gutierrez and Johan Hartman and Zuzana Kos and Anne-Vibeke Laenkholm and Arvydas Laurinavicius and {M. Levenson}, Richard and Rustin Mahboubi-Ardakani and {G. Mastropasqua}, Mauro and Sharon Nofech-Mozes and {C Osborne}, Kent and {M Penault-Llorca}, Frederique and Tammy Piper and Mary-Anne Quintayo and {T Rau}, Tilman and Stefan Reinhard and Stephanie Robertson and Roberto Salgado and Tomoharu Sugie and {van der Vegt}, Bert and Giuseppe Viale and {A. Zabaglo}, Lila and {F. Hayes}, Daniel and Mitch Dowsett and {O Nielson}, Torsten and {L Rimm}, David",

note = "Funding Information: BA is supported by The Swedish Society for Medical Research (Svenska S{\"a}llskapet f{\"o}r Medicinsk Forskning) Postdoctoral grant, Swedish Breast Cancer Association (Br{\"o}stcancerf{\"o}rbundet) Research grant 2021, The Fulbright Program and The Rosztoczy Foundation Scholarship Program. MD, DFH, RS (BCRF grant N° 17–194), (many others) and DLR are supported by the Breast Cancer Research Foundation. This work was supported by a generous grant from the Breast Cancer Research Foundation (DFH). Additional funding for the UK laboratories was received from Breakthrough Breast Cancer and the National Institute for Health Research Biomedical Research Centre at the Royal Marsden Hospital. Funding for the Ontario Institute for Cancer Research is provided by the Government of Ontario. JH is the Lilian McCullough Chair in Breast Cancer Surgery Research and the CBCF Prairies/NWT Chapter. Open access funding provided by Karolinska Institute. Funding Information: In the last 12 months, DLR has served as a consultant for advisor to Astra Zeneca, Agendia, Amgen, Cell Signaling Technology, Cepheid, Danaher, Konica-Minolta, Merck, PAIGE.AI, Regeneron, and Sanofi. TON reports a proprietary interest in PAM50/Prosigna and consultant work with Veracyte. JH was former member of the advisory board at Visiopharm A/S. JH has obtained speaker{\textquoteright}s honoraria or advisory board remunerations from Roche, Novartis, AstraZeneca, Eli Lilly, Pfizer and MSD. JH is co-founder and shareholder of Stratipath AB. JH has received institutional research grants from Cepheid and Novartis. DFH reports no research or personal financial support related to this study. DFH does report research support unrelated to this study provided to his institution during conduct from Menarini/Silicon BioSystems, Astra Zeneca, Eli Lilly Company, Merrimack Pharmaceuticals, Inc. (Parexel Intl Corp), Veridex and Janssen Diagnostics (Johnson & Johnson), Pfizer, and Puma Biotechnology, Inc. (subcontract Wash Univ St. Louis to Univ Mich). DFH also reports that his institution holds a patent regarding circulating tumor cell characterization for which DFH is the named investigator that was licensed to Menarini Silicon Biosystems and from which both received annual royalties, ending in January 2021. DFH reports personal income related to consulting or advisory board activities from BioVeca, Cellworks, Cepheid, EPIC Sciences, Freenome, Guardant, L-Nutra, Oncocyte, Macrogenics, Predictus BioSciences, Salutogenic Innovations, Turnstone Biologics, and Tempus. DFH reports personally held stock options from InBiomotion. BvdV reports speaker{\textquoteright}s honoraria or consultation/advisory board remunerations provided to his institution from Visiopharm, Philips, Merck/MSD and Diaceutics. GV reports receipt of grants/research supports from Roche/Genentech, Ventana Medical Systems, Dako/Agilent Technologies, and receipt of honoraria or consultation fees from Ventana, Dako/Agilent, Roche, MSD Oncology, AstraZeneca, Daiichi Sankyo, Pfizer, Eli Lilly. ZK has served in a paid advisory role to Eli Lilly. Unrelated to this study, SR is currently employed by Stratipath AB. RS reports non-financial support from Merck and Bristol Myers Squibb; research support from Merck, Puma Biotechnology, and Roche; and advisory board fees for Bristol Myers Squibb; and personal fees from Roche for an advisory board related to a trial-research project. RS has no COI related to this project. SF served as expert pathology consultant for Axdev Global Corp inc and as an expert advisory panel for Genomic Health in 2017. RML is co-founder and shareholder of MUSE Microscopy, Inc. and Histolix, Inc. RML served as consultant for Cell IDx, Inc., BriteSeed, Inc., ImmunoPhotonics, Inc., Pathology Watch, Inc. and Verily, Inc. FPL reports board meetings and conference support from Astrazeneca, Lilly, Novartis, Pfizer and Roche. JB served as consultant for Insight Genetics, Inc., BioNTech AG, Biotheranostics, Inc., Pfizer, Rna Diagnostics Inc., oncoXchange/MedcomXchange Communications Inc, Herbert Smith French Solicitors, OncoCyte Corporation. JB served as member of the scientific advisory board for MedcomXchange Communications Inc. JB reports honoraria from NanoString Technologies, Inc., Oncology Education, Biotheranostics, Inc., MedcomXchange Communications Inc. JB reports travel and accommodation expenses support from Biotheranostics, Inc., NanoString Technologies, Inc., Breast Cancer Society of Canada. JB received research funding from Thermo Fisher Scientific, Genoptix, Agendia, NanoString Technologies, Inc., Stratifyer GmbH, Biotheranostics, Inc. The remaining authors declare no competing interests. Publisher Copyright: {\textcopyright} 2022, The Author(s).",

year = "2022",

month = jun,

day = "21",

language = "English",

journal = "Modern Pathology",

issn = "0893-3952",

publisher = "Nature Publishing Group",

}

Systematically higher Ki67 scores on core biopsy samples compared to corresponding resection specimen in breast cancer: A multi-operator and multi-institutional study. / The International Ki67 in Breast Cancer Working Group of the Breast International Group & North American Breast Cancer Group (BIG-NABCG).
In: Modern Pathology, 21.06.2022.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Systematically higher Ki67 scores on core biopsy samples compared to corresponding resection specimen in breast cancer: A multi-operator and multi-institutional study

AU - The International Ki67 in Breast Cancer Working Group of the Breast International Group & North American Breast Cancer Group (BIG-NABCG)

AU - Acs, Balazs

AU - C.Y. Leung, Samuel

AU - M. Kidwell, Kelley

AU - Arun, Indu

AU - Augulis, Renaldas

AU - S Badve, Sunil

AU - Bai, Yalai

AU - L Bane, Anita

AU - Bartlett, John

AU - Bayani, Jane

AU - Bigras, Gilbert

AU - Blank, Annika

AU - Buikema, Henk

AU - C. Chang, Martin

AU - L. Dietz, Robin

AU - Dodson, Andrew

AU - Fineberg, Susan

AU - M. Focke, Cornelia

AU - Gao, Dongxia

AU - M. Gown, Allen

AU - Gutierrez, Carolina

AU - Hartman, Johan

AU - Kos, Zuzana

AU - Laenkholm, Anne-Vibeke

AU - Laurinavicius, Arvydas

AU - M. Levenson, Richard

AU - Mahboubi-Ardakani, Rustin

AU - G. Mastropasqua, Mauro

AU - Nofech-Mozes, Sharon

AU - C Osborne, Kent

AU - M Penault-Llorca, Frederique

AU - Piper, Tammy

AU - Quintayo, Mary-Anne

AU - T Rau, Tilman

AU - Reinhard, Stefan

AU - Robertson, Stephanie

AU - Salgado, Roberto

AU - Sugie, Tomoharu

AU - van der Vegt, Bert

AU - Viale, Giuseppe

AU - A. Zabaglo, Lila

AU - F. Hayes, Daniel

AU - Dowsett, Mitch

AU - O Nielson, Torsten

AU - L Rimm, David

N1 - Funding Information: BA is supported by The Swedish Society for Medical Research (Svenska Sällskapet för Medicinsk Forskning) Postdoctoral grant, Swedish Breast Cancer Association (Bröstcancerförbundet) Research grant 2021, The Fulbright Program and The Rosztoczy Foundation Scholarship Program. MD, DFH, RS (BCRF grant N° 17–194), (many others) and DLR are supported by the Breast Cancer Research Foundation. This work was supported by a generous grant from the Breast Cancer Research Foundation (DFH). Additional funding for the UK laboratories was received from Breakthrough Breast Cancer and the National Institute for Health Research Biomedical Research Centre at the Royal Marsden Hospital. Funding for the Ontario Institute for Cancer Research is provided by the Government of Ontario. JH is the Lilian McCullough Chair in Breast Cancer Surgery Research and the CBCF Prairies/NWT Chapter. Open access funding provided by Karolinska Institute. Funding Information: In the last 12 months, DLR has served as a consultant for advisor to Astra Zeneca, Agendia, Amgen, Cell Signaling Technology, Cepheid, Danaher, Konica-Minolta, Merck, PAIGE.AI, Regeneron, and Sanofi. TON reports a proprietary interest in PAM50/Prosigna and consultant work with Veracyte. JH was former member of the advisory board at Visiopharm A/S. JH has obtained speaker’s honoraria or advisory board remunerations from Roche, Novartis, AstraZeneca, Eli Lilly, Pfizer and MSD. JH is co-founder and shareholder of Stratipath AB. JH has received institutional research grants from Cepheid and Novartis. DFH reports no research or personal financial support related to this study. DFH does report research support unrelated to this study provided to his institution during conduct from Menarini/Silicon BioSystems, Astra Zeneca, Eli Lilly Company, Merrimack Pharmaceuticals, Inc. (Parexel Intl Corp), Veridex and Janssen Diagnostics (Johnson & Johnson), Pfizer, and Puma Biotechnology, Inc. (subcontract Wash Univ St. Louis to Univ Mich). DFH also reports that his institution holds a patent regarding circulating tumor cell characterization for which DFH is the named investigator that was licensed to Menarini Silicon Biosystems and from which both received annual royalties, ending in January 2021. DFH reports personal income related to consulting or advisory board activities from BioVeca, Cellworks, Cepheid, EPIC Sciences, Freenome, Guardant, L-Nutra, Oncocyte, Macrogenics, Predictus BioSciences, Salutogenic Innovations, Turnstone Biologics, and Tempus. DFH reports personally held stock options from InBiomotion. BvdV reports speaker’s honoraria or consultation/advisory board remunerations provided to his institution from Visiopharm, Philips, Merck/MSD and Diaceutics. GV reports receipt of grants/research supports from Roche/Genentech, Ventana Medical Systems, Dako/Agilent Technologies, and receipt of honoraria or consultation fees from Ventana, Dako/Agilent, Roche, MSD Oncology, AstraZeneca, Daiichi Sankyo, Pfizer, Eli Lilly. ZK has served in a paid advisory role to Eli Lilly. Unrelated to this study, SR is currently employed by Stratipath AB. RS reports non-financial support from Merck and Bristol Myers Squibb; research support from Merck, Puma Biotechnology, and Roche; and advisory board fees for Bristol Myers Squibb; and personal fees from Roche for an advisory board related to a trial-research project. RS has no COI related to this project. SF served as expert pathology consultant for Axdev Global Corp inc and as an expert advisory panel for Genomic Health in 2017. RML is co-founder and shareholder of MUSE Microscopy, Inc. and Histolix, Inc. RML served as consultant for Cell IDx, Inc., BriteSeed, Inc., ImmunoPhotonics, Inc., Pathology Watch, Inc. and Verily, Inc. FPL reports board meetings and conference support from Astrazeneca, Lilly, Novartis, Pfizer and Roche. JB served as consultant for Insight Genetics, Inc., BioNTech AG, Biotheranostics, Inc., Pfizer, Rna Diagnostics Inc., oncoXchange/MedcomXchange Communications Inc, Herbert Smith French Solicitors, OncoCyte Corporation. JB served as member of the scientific advisory board for MedcomXchange Communications Inc. JB reports honoraria from NanoString Technologies, Inc., Oncology Education, Biotheranostics, Inc., MedcomXchange Communications Inc. JB reports travel and accommodation expenses support from Biotheranostics, Inc., NanoString Technologies, Inc., Breast Cancer Society of Canada. JB received research funding from Thermo Fisher Scientific, Genoptix, Agendia, NanoString Technologies, Inc., Stratifyer GmbH, Biotheranostics, Inc. The remaining authors declare no competing interests. Publisher Copyright: © 2022, The Author(s).

PY - 2022/6/21

Y1 - 2022/6/21

M3 - Article

SN - 0893-3952

JO - Modern Pathology

JF - Modern Pathology

ER -